City Hill Ventures

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company employs an artificial intelligence drug discovery platform known as OPRA, which utilizes machine learning to analyze large-scale data sets and identify novel tumor biology, thereby accelerating drug development. Erasca is developing a pipeline of oncology drugs, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS-mutant melanoma and other RAS/MAPK-driven tumors. Additionally, the company is advancing ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, targeting key nodes in the RAS/MAPK signaling pathway. Through its research and collaborations, Erasca aims to provide precision oncology options that offer potential solutions for treating and possibly curing cancer.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company employs an artificial intelligence drug discovery platform known as OPRA, which utilizes machine learning to analyze large-scale data sets and identify novel tumor biology, thereby accelerating drug development. Erasca is developing a pipeline of oncology drugs, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS-mutant melanoma and other RAS/MAPK-driven tumors. Additionally, the company is advancing ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, targeting key nodes in the RAS/MAPK signaling pathway. Through its research and collaborations, Erasca aims to provide precision oncology options that offer potential solutions for treating and possibly curing cancer.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, offering two primary products: EB-001A for aesthetic applications and EB-001T for therapeutic indications. Bonti aims to provide solutions for patients experiencing muscle hyperactivity and associated musculoskeletal pain, addressing unmet medical needs with a long-acting, non-opioid local muscle relaxant that minimizes side effects common with existing treatments. Founded in 2015, Bonti was originally known as Endurance Biotech, Inc. and changed its name in August 2015. The company is headquartered in Newport Beach, California, and operates as a subsidiary of Allergan plc.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, offering two primary products: EB-001A for aesthetic applications and EB-001T for therapeutic indications. Bonti aims to provide solutions for patients experiencing muscle hyperactivity and associated musculoskeletal pain, addressing unmet medical needs with a long-acting, non-opioid local muscle relaxant that minimizes side effects common with existing treatments. Founded in 2015, Bonti was originally known as Endurance Biotech, Inc. and changed its name in August 2015. The company is headquartered in Newport Beach, California, and operates as a subsidiary of Allergan plc.

Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for muscle cramps, spasms, and spasticity related to neurological conditions and exercise-associated muscle cramps. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator that has completed an exploratory Phase II clinical trial in Australia for patients with multiple sclerosis. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps, which is marketed through its direct-to-consumer website and third-party platforms. In 2019, Flex Pharma was acquired by Salarius Pharmaceuticals, marking a significant shift in its operational structure.

Independa, Inc. is a technology company that develops cloud-based wellness and social engagement software solutions tailored for senior citizens. Founded in 2009 and based in San Diego, California, the company offers a range of products including AnyTV Companion, a remote care platform that facilitates social engagement, medication reminders, and activity monitoring. Additionally, it provides CloudCare, an enterprise solution that encompasses modules for remote care, wellness, and community involvement. Independa's offerings also include a caregiver dashboard, which simplifies monitoring for caregivers, and Angela, a solution designed to help seniors maintain their independence. The platform integrates various health monitoring devices and home sensors to keep track of vital signs and overall wellness. Independa serves a diverse clientele, including senior living communities, hospitals, and home care organizations, and has established a strategic partnership with LG Electronics to enhance its service delivery.

Independa, Inc. is a technology company that develops cloud-based wellness and social engagement software solutions tailored for senior citizens. Founded in 2009 and based in San Diego, California, the company offers a range of products including AnyTV Companion, a remote care platform that facilitates social engagement, medication reminders, and activity monitoring. Additionally, it provides CloudCare, an enterprise solution that encompasses modules for remote care, wellness, and community involvement. Independa's offerings also include a caregiver dashboard, which simplifies monitoring for caregivers, and Angela, a solution designed to help seniors maintain their independence. The platform integrates various health monitoring devices and home sensors to keep track of vital signs and overall wellness. Independa serves a diverse clientele, including senior living communities, hospitals, and home care organizations, and has established a strategic partnership with LG Electronics to enhance its service delivery.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

Independa, Inc. is a technology company that develops cloud-based wellness and social engagement software solutions tailored for senior citizens. Founded in 2009 and based in San Diego, California, the company offers a range of products including AnyTV Companion, a remote care platform that facilitates social engagement, medication reminders, and activity monitoring. Additionally, it provides CloudCare, an enterprise solution that encompasses modules for remote care, wellness, and community involvement. Independa's offerings also include a caregiver dashboard, which simplifies monitoring for caregivers, and Angela, a solution designed to help seniors maintain their independence. The platform integrates various health monitoring devices and home sensors to keep track of vital signs and overall wellness. Independa serves a diverse clientele, including senior living communities, hospitals, and home care organizations, and has established a strategic partnership with LG Electronics to enhance its service delivery.

Eclipse Therapeutics, Inc. is a private biotechnology company focused on the discovery and development of innovative therapeutics aimed at targeting cancer stem cells (CSCs). The company employs a unique biotechnology platform to create novel therapeutic products that address various forms of cancer treatment. Through its specialized approach, Eclipse Therapeutics seeks to advance the understanding and management of cancer by developing effective solutions that specifically target the underlying mechanisms of cancer stem cells.

Independa, Inc. is a technology company that develops cloud-based wellness and social engagement software solutions tailored for senior citizens. Founded in 2009 and based in San Diego, California, the company offers a range of products including AnyTV Companion, a remote care platform that facilitates social engagement, medication reminders, and activity monitoring. Additionally, it provides CloudCare, an enterprise solution that encompasses modules for remote care, wellness, and community involvement. Independa's offerings also include a caregiver dashboard, which simplifies monitoring for caregivers, and Angela, a solution designed to help seniors maintain their independence. The platform integrates various health monitoring devices and home sensors to keep track of vital signs and overall wellness. Independa serves a diverse clientele, including senior living communities, hospitals, and home care organizations, and has established a strategic partnership with LG Electronics to enhance its service delivery.